Project Grant R01AR083398
Award Date
8/7/24
Completion Date
6/30/29
Dollars Obligated
$1.7M
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
This $671,240 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to develop improved gene therapy approaches for Duchenne muscular dystrophy (DMD). The key objectives are to: 1) Refine technologies for expressing larger and more functional dystrophin or utrophin proteins using adeno-associated virus (AAV) vectors, 2) Develop enhanced...
The Regents of the University of Minnesota was awarded a $354,222 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will support research to investigate how the dystrophin-associated protein complex (DAPC) senses and adapts to biochemical, mechanical, and topographic cues in the cell microenvironment, and how this regulates myotube orientation and...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $1,601,933.00 to the University of Maryland, Baltimore to support research into developing C2 domain therapeutics for muscular dystrophy. The research aims to optimize engineered constructs of the DYSF-C2A domain to rescue deficits in calcium signaling and membrane repair in...
This $1,550,343 federal Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to determine the mechanisms by which the transcription factor DUX4 causes misregulation of RNA processing and quality control in facioscapulohumeral muscular dystrophy (FSHD). The research project, which will be conducted by the University of Colorado-Denver,...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $647,460 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Cornell University to support research on the mechanisms of mechanically-induced gene expression in skeletal muscle cells. The five-year project, running from September 1, 2024 to August 31, 2029, aims to define the nuclear mechanisms responsible for the ultra-rapid activation of mechanoresponsive genes in...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $151,471 to the University of California, Davis to research using collagenase to target collagen architecture in fibrotic skeletal muscle. The goal is to reduce muscle stiffness and promote tissue regeneration, with a focus on improving muscle function and regenerative capacity in...
This Project Grant award of $473,377 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research, supports research to modulate the stem cell niche and improve skeletal muscle regeneration. The key objectives are to: Interrogate how muscle cells arise and develop functional characteristics from human pluripotent stem cells (hPSCs) through analysis of myogenic commitment factors and inhibition of...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $525,048 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Children's Hospital Medical Center in Cincinnati, OH. The grant is titled "Development and Optimization of Skeletal Muscle Delivery Vehicles" and runs from July 8, 2024 to May 31, 2029. The project aims to develop novel gene therapy delivery vehicles, including lentiviruses and extracellular vesicles,...
This $692,292 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund research to understand the regulation of pediatric muscle regeneration and its implications for treating muscle diseases such as Duchenne muscular dystrophy (DMD). The 5-year project, running from April 2025 to March 2030, will be conducted by the Children's...
This federal Project Grant award of $219,605.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to identify the role of the mechanosensitive ion channel PIEZO1 in driving synovial fibrosis and inflammation in post-traumatic osteoarthritis (PTOA). The research will characterize the bi-directional regulation between PIEZO1 mechanotransduction and...